MTOR and acute lymphoblastic leukemia: Inhibition of the PI3K/AKT/mTOR pathway with the dual PI3K/mTOR inhibitor BEZ235 enhanced dexamethasone-induced anti-leukemic activity both in vitro and in vivo models of T-ALL [65, 66].